Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group - PubMed (original) (raw)

Clinical Trial

. 1995 Apr 22;345(8956):1008-12.

doi: 10.1016/s0140-6736(95)90755-6.

Affiliations

• PMID: 7723496
• DOI: 10.1016/s0140-6736(95)90755-6

Free article

Clinical Trial

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

H Brem et al. Lancet. 1995.

Free article

Abstract

Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant brain tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3.85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio = 0.67, p = 0.006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality = 32 of 72 [44%] vs 47 of 73 [64%], p = 0.02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.

PubMed Disclaimer

Comment in

• Treatment for glioma.
  Brewin TB. Brewin TB. Lancet. 1995 Jun 17;345(8964):1571. doi: 10.1016/s0140-6736(95)91117-0. Lancet. 1995. PMID: 7791456 No abstract available.

Similar articles

• Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
  Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, et al. Brem H, et al. J Neurosurg. 1991 Mar;74(3):441-6. doi: 10.3171/jns.1991.74.3.0441. J Neurosurg. 1991. PMID: 1993909 Clinical Trial.
• Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
  Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI. Brem H, et al. J Neurosurg. 1994 Feb;80(2):283-90. doi: 10.3171/jns.1994.80.2.0283. J Neurosurg. 1994. PMID: 8283268
• Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
  Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium. Olivi A, et al. J Clin Oncol. 2003 May 1;21(9):1845-9. doi: 10.1200/JCO.2003.09.041. J Clin Oncol. 2003. PMID: 12721262 Clinical Trial.
• Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
  Gallia GL, Brem S, Brem H. Gallia GL, et al. J Natl Compr Canc Netw. 2005 Sep;3(5):721-8. doi: 10.6004/jnccn.2005.0042. J Natl Compr Canc Netw. 2005. PMID: 16194460 Review.
• Polymers to treat brain tumours.
  Brem H. Brem H. Biomaterials. 1990 Nov;11(9):699-701. doi: 10.1016/0142-9612(90)90030-t. Biomaterials. 1990. PMID: 2090306 Review.

Cited by

• Convection-enhanced drug delivery for gliomas.
  Healy AT, Vogelbaum MA. Healy AT, et al. Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S59-67. doi: 10.4103/2152-7806.151337. eCollection 2015. Surg Neurol Int. 2015. PMID: 25722934 Free PMC article.
• Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy.
  Mangraviti A, Tyler B, Brem H. Mangraviti A, et al. Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S78-84. doi: 10.4103/2152-7806.151345. eCollection 2015. Surg Neurol Int. 2015. PMID: 25722936 Free PMC article.
• Leveraging next generation materials for cancer neuroscience therapies in the central nervous system.
  Bernstock JD, Johnston BR, Friedman GK, Chiocca EA, Langer R, Srinivasan SS. Bernstock JD, et al. Nat Rev Mater. 2024 Apr 22;9:298-300. doi: 10.1038/s41578-024-00681-2. Nat Rev Mater. 2024. PMID: 39234424 Free PMC article. No abstract available.
• Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis.
  Mu F, Lucas JT Jr, Watts JM, Johnson AJ, Daniel Bourland J, Laxton AW, Chan MD, Tatter SB. Mu F, et al. J Clin Neurosci. 2015 Mar;22(3):561-5. doi: 10.1016/j.jocn.2014.08.020. Epub 2015 Jan 2. J Clin Neurosci. 2015. PMID: 25560387 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information